Integrated Filing — IndAS



General information about company

Scrip Code 532296
NSE Symbol GLENMARK
MSEI Symbol NOTLISTED
ISIN INE935A01035
Name of company Glenmark Pharmaceuticals Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 14-11-2025   14:00:00
End date and time of board meeting 14-11-2025   16:42:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 14-02-2025
Indicate Company website link for updated RPT policy of the Company https://glenmark.b-cdn.net/gpl_pdfs/about_us/Policy%20on%20RPT%20and%20its%20Materiality.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company is debt free.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1,53,866.00 3,93,358.80
Other income 28,575.60 35,509.10
Total income 1,82,441.60 4,28,867.90
2 Expenses
(a) Cost of materials consumed 66,782.00 1,34,506.00
(b) Purchases of stock-in-trade 9,131.30 19,063.80
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (10,285.00) (16,126.00)
(d) Employee benefit expense 45,367.50 86,211.80
(e) Finance costs 2,339.60 3,885.40
(f) Depreciation, depletion and amortisation expense 5,893.40 11,657.30
(f) Other Expenses
1 Other Expenses 60,670.00 1,14,687.10
Total other expenses 60,670.00 1,14,687.10
Total expenses 1,79,898.80 3,53,885.40
3 Total profit before exceptional items and tax 2,542.80 74,982.50
4 Exceptional items (93,179.40) (1,25,502.60)
5 Total profit before tax (90,636.60) (50,520.10)
6 Tax expense
7 Current tax (7,017.20) 0.00
8 Deferred tax (9,700.50) (9,623.80)
9 Total tax expenses (16,717.70) (9,623.80)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (73,918.90) (40,896.30)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (73,918.90) (40,896.30)
17 Other comprehensive income net of taxes (1,462.00) (1,515.40)
18 Total Comprehensive Income for the period (75,380.90) (42,411.70)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,822.00 2,822.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -26.19 -14.49
Diluted earnings (loss) per share from continuing operations -26.19 -14.49
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -26.19 -14.49
Diluted earnings (loss) per share from continuing and discontinued operations -26.19 -14.49
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) As cell of point no. 19 are blocked. The details of the same is mentioned below: Total profit/(Loss) attributable to owners of parent is (7,391.89) Total profit/(Loss) attributable to non-controlling interests is 0 As cell of point no. 20 are blocked. The details of the same is mentioned below: Total comprehensive income for the period attribtable to owners of parent is (7,538.09) Total comprehensive income for the period attribtable non-controlling interests is 0



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,78,192.20
Capital work-in-progress 16,819.20
Investment property 0.00
Goodwill 0.00
Other intangible assets 18,403.00
Intangible assets under development 4,672.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 15,20,220.10
Trade receivables, non-current 0.00
Loans, non-current 5,34,037.70
Other non-current financial assets 4,554.00
Total non-current financial assets 20,58,811.80
Deferred tax assets (net) 4,074.50
Other non-current assets 17,534.00
Total non-current assets 22,98,506.70
2 Current assets
Inventories 1,39,466.20
Current financial asset
Current investments 0.00
Trade receivables, current 2,61,466.60
Cash and cash equivalents 8,547.10
Bank balance other than cash and cash equivalents 124.50
Loans, current 0.00
Other current financial assets 22,144.00
Total current financial assets 2,92,282.20
Current tax assets (net) 0.00
Other current assets 84,066.50
Total current assets 5,15,814.90
3 Non-current assets classified as held for sale 24,046.20
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 28,38,367.80
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,822.00
Other equity 23,91,127.90
Total equity attributable to owners of parent 23,93,949.90
Non controlling interest
Total equity 23,93,949.90
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 50,915.50
Total non-current financial liabilities 50,915.50
Provisions, non-current 0.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 50,915.50
Current liabilities
Current financial liabilities
Borrowings, current 35,872.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2,654.40
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,49,229.20
Total Trade payable 2,51,883.60
Other current financial liabilities 85,107.40
Total current financial liabilities 3,72,863.00
Other current liabilities 4,348.00
Provisions, current 12,787.60
Current tax liabilities (Net) 2,132.30
Deferred government grants, Current 0.00
Total current liabilities 3,92,130.90
3 Liabilities directly associated with assets in disposal group classified as held for sale 1,371.50
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 4,44,417.90
Total equity and liabilites 28,38,367.80
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -171020000 -179220000
Total Amount of items that will not be reclassified to profit and loss (1,710.20) (1,792.20)
2 Income tax relating to items that will not be reclassified to profit or loss (248.20) (276.80)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (1,462.00) (1,515.40)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (50,520.10)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 3,885.40
Adjustments for decrease (increase) in inventories (24,002.70)
Adjustments for decrease (increase) in trade receivables, current (83,817.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (37,465.90)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 58,177.40
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 1,25,502.60
Adjustments for depreciation and amortisation expense 11,657.30
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.30
Adjustments for interest income 8,983.60
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (1.60)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (1.60)
Other adjustments to reconcile profit (loss) 1,070.30
Other adjustments for non-cash items (13,807.70)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 32,212.60
Net cash flows from (used in) operations (18,307.50)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,830.20
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (21,137.70)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 1.60
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 88.20
Purchase of property, plant and equipment 14,175.30
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 57,609.50
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.30
Interest received 12,382.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 4.60
Net cash flows from (used in) investing activities 55,911.70
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 75.90
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 34,124.60
Payments of lease liabilities 2,052.60
Dividends paid 4.60
Interest paid 3,263.90
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (39,369.80)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4,595.80)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (2.20)
Net increase (decrease) in cash and cash equivalents (4,598.00)
Cash and cash equivalents cash flow statement at beginning of period 13,145.10
Cash and cash equivalents cash flow statement at end of period 8,547.10





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 0.50 0.00 0.00
2 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Sale of goods or services - 232.30 0.00 0.00
3 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 39.30 0.00 0.00
4 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 1.70 0.00 0.00
5 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Sale of goods or services - 389.90 0.00 0.00
6 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Purchase of goods or services - 27.90 0.00 0.00
7 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Any other transaction Reimbursement Charges Receievd - 26.70 0.00 0.00
8 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Sale of goods or services - 7,522.50 0.00 0.00
9 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 114.30 0.00 0.00
10 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Purchase of goods or services - 13,778.90 0.00 0.00
11 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Purchase of goods or services - 1,926.00 0.00 0.00
12 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Sale of goods or services - 5,539.00 0.00 0.00
13 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Any other transaction Sales of Services - 21.70 0.00 0.00
14 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 131.20 0.00 0.00
15 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Purchase of goods or services - 2,509.70 0.00 0.00
16 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 1.20 0.00 0.00
17 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Sale of goods or services - 5,523.10 0.00 0.00
18 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 4.90 0.00 0.00
19 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly Owned Subsidary Sale of goods or services - 1.80 0.00 0.00
20 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Purchase of goods or services - 1,079.70 0.00 0.00
21 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 271.10 0.00 0.00
22 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Sale of goods or services - 11,255.80 0.00 0.00
23 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Sale of Services - 359.30 0.00 0.00
24 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 2,275.70 0.00 0.00
25 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U. Wholly Owned Subsidary Sale of goods or services - 4,273.20 0.00 0.00
26 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Sale of Services - 25.90 0.00 0.00
27 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U. Wholly Owned Subsidary Any other transaction Sale of Services - 39.70 0.00 0.00
28 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U. Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 92.30 0.00 0.00
29 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Purchase of goods or services - 80.00 0.00 0.00
30 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Sale of goods or services - 3,246.30 0.00 0.00
31 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Sale of Services - 3.60 0.00 0.00
32 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 48.00 0.00 0.00
33 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidary Sale of goods or services - 6,113.40 0.00 0.00
34 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidary Any other transaction Sale of Services - 3.80 0.00 0.00
35 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 314.10 0.00 0.00
36 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 198.90 0.00 0.00
37 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidary Sale of goods or services - 809.40 0.00 0.00
38 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 28.90 0.00 0.00
39 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Purchase of fixed assets - 516.40 0.00 0.00
40 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 419.30 0.00 0.00
41 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Sale of goods or services - 13,648.70 0.00 0.00
42 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Sale of Services - 2.80 0.00 0.00
43 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Sale of goods or services - 17.00 0.00 0.00
44 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Sale of Services - 0.60 0.00 0.00
45 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 5.00 0.00 0.00
46 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceuticals Ltda Brazil Wholly Owned Subsidary Any other transaction Reimbursement Charges Paid - 13.90 0.00 0.00
47 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 139.70 0.00 0.00
48 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Purchase of goods or services - 94.40 0.00 0.00
49 Glenmark Pharmaceuticals Europe Ltd, UK Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 31.90 0.00 0.00
50 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 2.40 0.00 0.00
51 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 51.60 0.00 0.00
52 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals BV Wholly Owned Subsidary Purchase of goods or services - 291.70 0.00 0.00
53 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 19.70 0.00 0.00
54 Glenmark Pharmaceuticals Europe Ltd, UK Viso Farmaceutica S.L.U. Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 12.10 0.00 0.00
55 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidary Any other transaction Reimbursement Charges Received - 16.30 0.00 0.00
56 Glenmark Pharmaceuticals Europe Ltd, UK Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Interest on loan - 34.70 0.00 0.00
57 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Interest on loan - 759.30 0.00 0.00
58 Glenmark Pharmaceuticals Kenya Limited Glenmark Generics S.A. Wholly Owned Subsidary Purchase of goods or services - 31.20 0.00 0.00
59 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Generics S.A. Wholly Owned Subsidary Purchase of goods or services - 294.30 0.00 0.00
60 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Farmaceuticals Ltda Brazil Wholly Owned Subsidary Purchase of goods or services - 215.50 0.00 0.00
61 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. -Peru Wholly Owned Subsidary Sale of goods or services - 87.30 0.00 0.00
62 Glenmark Farmaceuticals Ltda Brazil Glenmark Ecuador Wholly Owned Subsidary Sale of goods or services - 8.40 0.00 0.00
63 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly Owned Subsidary Purchase of goods or services - 928.50 0.00 0.00
64 Glenmark Ecuador Glenmark Generics S.A. Wholly Owned Subsidary Purchase of goods or services - 69.00 0.00 0.00
65 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Reimbursement charges paid - 3.10 0.00 0.00
66 Glenmark Pharmaceuticals Europe Ltd, UK GLENMAK IMPEX LLC Wholly Owned Subsidary Any other transaction Reimbursement charges paid - 1.90 0.00 0.00
67 Glenmark Pharmaceuticals Europe Ltd, UK Viso Farmaceutica S.L.U. Wholly Owned Subsidary Any other transaction Reimbursement charges paid - 0.20 0.00 0.00
68 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 0.50
69 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidary Any other transaction Receivable - 0.00 168.60 284.90
70 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidary Any other transaction Payable - 0.00 8.90 0.80
71 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidary Any other transaction Receivable - 0.00 43.50 68.10
72 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Ukraine LLC Wholly Owned Subsidary Any other transaction Receivable - 0.00 0.10 0.20
73 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Any other transaction Payable - 0.00 730.60 2,211.10
74 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidary Any other transaction Receivable - 0.00 2,090.30 6,529.60
75 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidary Any other transaction Payable - 0.00 409.90 952.10
76 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidary Any other transaction Receivable - 0.00 4,329.60 4,730.50
77 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidary Any other transaction Payable - 0.00 1,275.30 1,615.10
78 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidary Any other transaction Receivable - 0.00 5,081.30 7,418.70
79 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly Owned Subsidary Any other transaction Payable - 0.00 1,527.60 3,093.90
80 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly Owned Subsidary Any other transaction Receivable - 0.00 4,991.70 2,658.00
81 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U., Spain Wholly Owned Subsidary Any other transaction Receivable - 0.00 1,558.10 4,433.10
82 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Payable - 0.00 30.20 84.40
83 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Receivable - 0.00 1,725.00 329.60
84 Glenmark Pharmaceuticals s.r.o. Glenmark Nordics SE Wholly Owned Subsidary Any other transaction Receivable - 0.00 13,419.20 12,149.80
85 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Payable - 0.00 1,520.40 1,644.80
86 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Receivable - 0.00 4,600.40 2,692.10
87 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Receivable - 0.00 148.30 190.20
88 Glenmark Pharmaceuticals s.r.o. Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 23.00 25.90
89 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Receivable - 0.00 1,020.20 1,746.30
90 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Payable - 0.00 711.50 0.00
91 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceuticals Ltda Brazil Wholly Owned Subsidary Any other transaction Receivable - 0.00 0.00 14.70
92 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Payable - 0.00 83.60 17.10
93 Glenmark Pharmaceuticals Europe Limited Viso Farmaceutica S.L.U., Spain Wholly Owned Subsidary Any other transaction Receivable - 0.00 21.10 35.30
94 Glenmark Pharmaceuticals Europe Limited Viso Farmaceutica S.L.U., Spain Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 0.20
95 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Payable - 0.00 388.60 744.40
96 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals BV Wholly Owned Subsidary Any other transaction Receivable - 0.00 63.50 89.30
97 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 5.10
98 Glenmark Pharmaceuticals Europe Limited Glenmark Nordics SE Wholly Owned Subsidary Any other transaction Receivable - 0.00 41.20 5.80
99 Glenmark Pharmaceuticals Europe Limited Glenmark Impex L.L.C Wholly Owned Subsidary Any other transaction Receivable - 0.00 6.90 5.40
100 Glenmark Pharmaceuticals Europe Limited Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Receivable - 0.00 59.60 100.40
101 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Payable - 0.00 14.50 115.20
102 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Receivable - 0.00 110.70 175.10
103 Glenmark Pharmaceuticals Europe Limited Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 5.80 5.50
104 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals Mexico SA de CV Wholly Owned Subsidary Any other transaction Receivable - 0.00 2.50 2.70
105 Glenmark Pharmaceuticals Europe Limited Glenmark Farmaceuticals Ltda Brazil Wholly Owned Subsidary Any other transaction Receivable - 0.00 38.50 41.60
106 Glenmark Pharmaceuticals Europe Limited Sintesy Pharma S.r.l. Wholly Owned Subsidary Any other transaction Loan given - 0.00 1,143.80 1,325.40
107 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidary Any other transaction Loan Payable - 0.00 28,219.30 32,456.50
108 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Receivable - 0.00 3.30 6.20
109 Glenmark Arzneimittel GmbH, Germany Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidary Any other transaction Receivable - 0.00 240.80 271.40
110 Glenmark Pharmaceuticals Kenya Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd Wholly Owned Subsidary Any other transaction Payable - 0.00 12.60 12.90
111 Glenmark Pharmaceuticals Kenya Limited Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 32.70
112 Glenmark Pharmaceuticals Kenya Limited Glenmark Egypt Wholly Owned Subsidary Any other transaction Receivable - 0.00 21.00 19.40
113 Glenmark Pharmaceuticals South Africa (Pty) Ltd Glenmark South Africa (Pty) Ltd Wholly Owned Subsidary Any other transaction Loan given - 0.00 4,403.70 4,857.30
114 Glenmark Pharmaceuticals South Africa (Pty) Ltd Glenmark South Africa (Pty) Ltd Wholly Owned Subsidary Any other transaction Investment - 0.00 259.00 259.00
115 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 61.10
116 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Mexico SA de CV Wholly Owned Subsidary Any other transaction Receivable - 0.00 163.70 754.70
117 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. Peru Wholly Owned Subsidary Any other transaction Payable - 0.00 53.70 3.80
118 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 111.70 116.10
119 Glenmark Farmaceuticals Ltda Brazil Glenmark Ecuador Wholly Owned Subsidary Any other transaction Receivable - 0.00 25.40 3.50
120 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Payable - 0.00 358.00 270.80
121 Glenmark Pharmaceuticals Venezuela Glenmark Generics S.A. Wholly Owned Subsidary Any other transaction Payable - 0.00 170.00 150.00
122 Glenmark Pharmaceuticals Ltd. -Peru Glenmark Ecuador Wholly Owned Subsidary Any other transaction Payable - 0.00 26.10 0.00
123 Glenmark Holding S.A. GLENMARK THERAPEUTICS INC. Wholly Owned Subsidary Investment - 0.00 24,817.00 24,817.00
124 Glenmark Holding S.A. GLENMARK FARMACEUTICA LTDA Wholly Owned Subsidary Investment - 17,284.00 1,56,705.20 1,73,989.20
125 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS S.r.o Wholly Owned Subsidary Investment - 0.00 71,947.80 71,947.80
126 Glenmark Holding S.A. GLENAMRK PHARMACEUTICALS SP Z.O.O Wholly Owned Subsidary Investment - 0.00 3,678.30 3,678.30
127 Glenmark Holding S.A. Glenmark Specialty SA Wholly Owned Subsidary Investment - 0.00 1,51,866.90 1,51,866.90
128 Glenmark Holding S.A. Viso Farmaceutica, SL Wholly Owned Subsidary Investment - 0.00 2.10 2.10
129 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS INC. Wholly Owned Subsidary Investment - 0.00 3,83,635.40 3,83,635.40
130 Glenmark Holding S.A. Glenmark Pharmaceuticals Canada Inc Wholly Owned Subsidary Investment - 0.00 1,075.70 1,075.70
131 Glenmark Holding S.A. GLENMARK GENERICS S.A. Wholly Owned Subsidary Investment - 6,313.80 1,05,537.10 1,11,850.90
132 Glenmark Holding S.A. Glenmark Arzneimittel GmBH Wholly Owned Subsidary Investment - 0.00 1,068.40 1,068.40
133 Glenmark Holding S.A. Glenmark Pharmaceuticals BV Wholly Owned Subsidary Investment - 0.00 14.80 14.80
134 Glenmark Holding S.A. Glenmark Pharmaceuticals Distribution Wholly Owned Subsidary Investment - 0.00 16,461.20 16,461.20
135 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS NORDIC AB Wholly Owned Subsidary Investment - 0.00 1,739.30 1,739.30
136 Glenmark Holding S.A. Glenmark Ukraine LLC Wholly Owned Subsidary Investment - 0.00 461.50 461.50
137 Glenmark Holding S.A. ICHNOS GLENMARK INNOVATION INC. Wholly Owned Subsidary Investment - 3,197.50 4,08,886.90 4,12,084.40
138 Glenmark Holding S.A. Sintesy Pharma S.R.L. Wholly Owned Subsidary Investment - 0.00 1,559.50 1,559.50
139 Glenmark Holding S.A. Glenmark Farmaceutica Spa., Chile Wholly Owned Subsidary Investment - 86.40 124.20 210.60
140 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Austria Wholly Owned Subsidary Investment - 0.00 522.50 522.50
141 Glenmark Specialty S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Payable - 0.00 479.90 666.30
142 Glenmark Specialty S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Expense - 130.30 0.00 0.00
143 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidary Any other transaction Payable - 0.00 1,774.90 2,402.00
144 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidary Any other transaction Expense - 532.50 0.00 0.00
145 Glenmark Specialty S.A. IGI Therapeutics SA Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 0.00
146 Glenmark Specialty S.A. GLENMARK FARMACÊUTICA LTDA Wholly Owned Subsidary Any other transaction Payable - 0.00 0.00 0.50
147 Glenmark Specialty S.A. GLENMARK FARMACÊUTICA LTDA Wholly Owned Subsidary Any other transaction Expense - 0.40 0.00 0.00
148 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidary Any other transaction Payable - 0.00 255.00 287.40
149 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidary Any other transaction Payable - 0.00 18.30 0.00
150 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidary Any other transaction Receivable - 0.00 17,175.00 27,532.20
151 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidary Sale of goods or services - 14,143.30 0.00 0.00
152 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidary Any other transaction Receivable - 0.00 258.70 0.00
153 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidary Sale of goods or services - 96.80 0.00 0.00
154 Glenmark Specialty S.A. Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly Owned Subsidary Any other transaction Receivable - 0.00 282.10 271.00
155 Glenmark Specialty S.A. Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly Owned Subsidary Sale of goods or services - 267.00 0.00 0.00
156 Glenmark Specialty S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidary Any other transaction Receivable - 0.00 298.10 531.20
157 Glenmark Specialty S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidary Sale of goods or services - 210.60 0.00 0.00
158 Glenmark Specialty S.A. Glenmark Impex LLC Wholly Owned Subsidary Any other transaction Receivable - 0.00 5,082.20 8,456.60
159 Glenmark Specialty S.A. Glenmark Impex LLC Wholly Owned Subsidary Sale of goods or services - 3,083.40 0.00 0.00
160 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidary Any other transaction Receivable - 0.00 76,647.90 60,872.40
161 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidary Sale of goods or services - 22,550.90 0.00 0.00
162 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidary Any other transaction Receivable - 0.00 1,138.80 3,172.20
163 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidary Sale of goods or services - 1,932.60 0.00 0.00
164 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 116.30 13.40
165 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidary Any other transaction Service income - 12.80 0.00 0.00
166 Glenmark Specialty S.A. Glenmark Pharmaceuticals FZE Wholly Owned Subsidary Any other transaction Receivable - 0.00 328.50 341.30
167 Glenmark Specialty S.A. Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly Owned Subsidary Any other transaction Receivable - 0.00 0.00 3,472.30
168 Glenmark Specialty S.A. Glenmark Pharmaceuticals Australia Wholly Owned Subsidary Any other transaction Receivable - 0.00 879.70 956.50
169 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 67,601.00 1,01,052.60 Loan 4.50 5 years Unsecured Business purpose
170 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidary Interest received - 1,885.80 0.00 0.00
171 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidary Any other transaction Loan Given - 33,766.60 0.00 0.00
172 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp Z.o.o Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 1,288.60 973.30 Loan 5.00 5 years Unsecured Business purpose
173 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp Z.o.o Wholly Owned Subsidary Interest received - 32.80 0.00 0.00
174 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 2,01,573.10 4,06,407.10 Loan 5.00 3 years Unsecured Business purpose
175 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly Owned Subsidary Interest received - 7,294.20 0.00 0.00
176 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly Owned Subsidary Any other transaction Loan Given - 2,51,501.70 0.00 0.00
177 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 0.00 3,066.60 Loan 5.00 3 years Unsecured Business purpose
178 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidary Interest received - 3.80 0.00 0.00
179 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidary Any other transaction Loan Given - 2,907.70 0.00 0.00
180 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 0.00 2,665.70 Loan 5.00 3 years Unsecured Business purpose
181 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidary Interest received - 2.40 0.00 0.00
182 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidary Any other transaction Loan given - 2,527.00 0.00 0.00
183 Glenmark Holding S.A. Glenmark Pharmaceuticals Colombia Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 0.00 1,777.20 Loan 5.00 3 years Unsecured Business purpose
184 Glenmark Holding S.A. Glenmark Pharmaceuticals Colombia Wholly Owned Subsidary Interest received - 1.60 0.00 0.00
185 Glenmark Holding S.A. Glenmark Pharmaceuticals Colombia Wholly Owned Subsidary Any other transaction Loan given - 1,684.70 0.00 0.00
186 Glenmark Holding S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 0.00 222.10 Loan 5.00 3 years Unsecured Business purpose
187 Glenmark Holding S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidary Interest received - 0.20 0.00 0.00
188 Glenmark Holding S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidary Any other transaction Loan given - 211.10 0.00 0.00
189 Glenmark Holding S.A. Glenmark Pharmaceuticals Ecuador Wholly Owned Subsidary Any other transaction Loan Receivable - 0.00 0.00 1,777.20 Loan 5.00 1 Year Unsecured Business purpose
190 Glenmark Holding S.A. Glenmark Pharmaceuticals Ecuador Wholly Owned Subsidary Interest received - 1.60 0.00 0.00
191 Glenmark Holding S.A. Glenmark Pharmaceuticals Ecuador Wholly Owned Subsidary Any other transaction Loan given - 1,684.70 0.00 0.00
192 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly Owned Subsidary Interest received - 212.00 0.00 0.00
193 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly Owned Subsidary Any other transaction Loan given - 20,875.40 0.00 0.00 Loan 5.00 1 Year Unsecured Business purpose
194 Glenmark Holding S.A. Glenmark Farmacêutica Ltda Wholly Owned Subsidary Interest received - 0.00 44.00 45.70
195 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly Owned Subsidary Any other transaction Dividend Receivable - 0.00 1,38,146.30 1,68,852.40
196 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly Owned Subsidary Any other transaction Dividend Receivable - 24,155.60 0.00 0.00
197 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Loan Payable - 0.00 19,618.50 3,917.00 Loan 3.32 1 Year Unsecured Business purpose
198 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Interest paid - 380.50 0.00 0.00
199 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Loan Taken - 9,234.80 0.00 0.00
200 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Germany Wholly Owned Subsidary Interest paid - 587.50 0.00 0.00
201 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidary Any other transaction Loan Payable - 0.00 14,235.40 14,904.10 Loan 3.32 1 Year Unsecured Business purpose
202 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidary Interest paid - 205.80 0.00 0.00
203 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidary Any other transaction Loan Taken - 14,279.40 0.00 0.00
204 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidary Any other transaction Expense Payable - 0.00 116.30 13.40
205 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidary Any other transaction Expense - 12.80 0.00 0.00
206 Glenmark Holding S.A. IGI Therapeutics SA Wholly Owned Subsidary Interest paid - 1,128.00 0.00 0.00
207 Glenmark Holding S.A. IGI Therapeutics SA Wholly Owned Subsidary Any other transaction Loan taken - 5,70,372.00 0.00 0.00
208 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Germany Wholly Owned Subsidary Any other transaction Loan Payable - 0.00 42,935.00 31,133.10 Loan 3.32 1 Year Unsecured Business purpose
209 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly Owned Subsidary Loan - 0.00 15,266.90 13,940.60 Loan 5.00 Long Term Unsecured Operating expense Textual Information(1)
210 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly Owned Subsidary Investment - 0.00 85,032.00 85,032.00
211 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly Owned Subsidary Interest received - 581.10 0.00 0.00
212 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly Owned Subsidary Any other transaction Other Income/ Receivable - 6,690.50 16,727.40 24,263.50
213 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly Owned Subsidary Any other transaction Expenses reimbursed - 5.40 0.00 0.00
214 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly Owned Subsidary Any other transaction Issue of Share capital - 6.10 823.10 829.20
215 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly Owned Subsidary Any other transaction Issue of Share Premium - 3,169.70 4,27,237.80 4,30,407.60
216 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly Owned Subsidary Any other transaction Dividend Payable - 0.00 1,38,164.80 1,68,903.50
217 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly Owned Subsidary Dividend paid - 24,643.40 0.00 0.00
218 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly Owned Subsidary Interest paid - 216.00 0.00 0.00
219 Ichnos Glenmark innovation Therapeutics SA Glenmark Holding S.A. Wholly Owned Subsidary Interest received - 1,633.00 0.00 0.00
220 Ichnos Glenmark innovation Therapeutics SA Glenmark Holding S.A. Wholly Owned Subsidary Loan - 0.00 0.00 5,87,757.90 Loan 4.75 Long Term Unsecured Operating expense Textual Information(2)
221 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C Wholly Owned Subsidary Investment - 0.00 14,356.10 14,356.10
222 Glenmark Pharmaceuticals Limited Glenmark Philippines Inc. Wholly Owned Subsidary Investment - 0.00 1,167.00 1,167.00
223 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly Owned Subsidary Investment - 0.00 977.20 977.20
224 Glenmark Pharmaceuticals Limited Glenmark Holding S.A. Wholly Owned Subsidary Investment - 0.00 14,32,317.50 14,32,317.50
225 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Pty Ltd Wholly Owned Subsidary Investment - 0.00 1,017.20 1,017.20
226 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E. Wholly Owned Subsidary Investment - 0.00 6,342.70 4,217.40
227 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE Wholly Owned Subsidary Investment - 0.00 129.20 129.20
228 Glenmark Pharmaceuticals Limited Glenmark Dominicana SRL Wholly Owned Subsidary Investment - 0.00 2.30 2.30
229 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd Wholly Owned Subsidary Investment - 0.00 971.80 971.80
230 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia SAS, Colombia Wholly Owned Subsidary Investment - 0.00 5,774.70 5,774.70
231 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC Wholly Owned Subsidary Investment - 0.00 8,277.90 8,277.90
232 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Wholly Owned Subsidary Investment - 0.00 16,952.90 16,952.90
233 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd., U.K. Wholly Owned Subsidary Investment - 0.00 5,782.30 5,782.30
234 Glenmark Pharmaceuticals Limited Glenmark South Africa (pty) Ltd Wholly Owned Subsidary Investment - 0.00 10,442.00 10,442.00
235 Glenmark Pharmaceuticals Limited Glenmark Uruguay S.A. Wholly Owned Subsidary Investment - 0.00 7,745.30 7,745.30
236 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd Wholly Owned Subsidary Investment - 0.00 37.20 37.20
237 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ecuador S.A. Wholly Owned Subsidary Investment - 0.00 2,454.90 2,454.90
238 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Singapore Pte. Ltd. Wholly Owned Subsidary Investment - 0.00 327.30 327.30
239 Glenmark Pharmaceuticals Limited Glenmark Healthcare Limited Wholly Owned Subsidary Investment - 0.00 905.00 905.00
240 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Limited Wholly Owned Subsidary Investment - 0.00 0.00 5.00
241 Glenmark Pharmaceuticals Limited Glenmark Farmaceutica Ltda., Brazil Wholly Owned Subsidary Sale of goods or services - 6,878.90 0.00 0.00
242 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Wholly Owned Subsidary Sale of goods or services - 437.50 0.00 0.00
243 Glenmark Pharmaceuticals Limited Glenmark Phillipines Inc., Philippines Wholly Owned Subsidary Sale of goods or services - 1,710.30 0.00 0.00
244 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C., Russia Wholly Owned Subsidary Sale of goods or services - 29,520.50 0.00 0.00
245 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly Owned Subsidary Sale of goods or services - 993.20 0.00 0.00
246 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC., Wholly Owned Subsidary Sale of goods or services - 352.30 0.00 0.00
247 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd. Wholly Owned Subsidary Sale of goods or services - 346.10 0.00 0.00
248 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd. Wholly Owned Subsidary Sale of goods or services - 1,787.60 0.00 0.00
249 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia Ltda. Wholly Owned Subsidary Sale of goods or services - 635.50 0.00 0.00
250 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico, S.A. Wholly Owned Subsidary Sale of goods or services - 4,906.90 0.00 0.00
251 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn Bhd. Wholly Owned Subsidary Sale of goods or services - 2,465.40 0.00 0.00
252 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly Owned Subsidary Sale of goods or services - 77,692.00 0.00 0.00
253 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidary Sale of goods or services - 18,607.80 0.00 0.00
254 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidary Sale of goods or services - 14,909.10 0.00 0.00
255 Glenmark Pharmaceuticals Limited Glenmark Pharmaceutical FZE UAE Wholly Owned Subsidary Sale of goods or services - 193.70 0.00 0.00
256 Glenmark Pharmaceuticals Limited GLENMARK GENERICS S.A. Wholly Owned Subsidary Sale of goods or services - 127.60 0.00 0.00
257 Glenmark Pharmaceuticals Limited GLENMARK PHARMACEUTICALS ECUADOR Wholly Owned Subsidary Sale of goods or services - 409.10 0.00 0.00
258 Glenmark Pharmaceuticals Limited Glenmark Therapeutics Inc., USA Wholly Owned Subsidary Sale of goods or services - 908.80 0.00 0.00
259 Glenmark Pharmaceuticals Limited Glenmark Ukrain LLC Wholly Owned Subsidary Sale of goods or services - 1,079.70 0.00 0.00
260 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc. Wholly Owned Subsidary Sale of goods or services - 4,149.90 0.00 0.00
261 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidary Sale of goods or services - 10.70 0.00 0.00
262 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidary Sale of goods or services - 22,108.20 0.00 0.00
263 Glenmark Pharmaceuticals Limited IGI Therapeutics SA Wholly Owned Subsidary Any other transaction Other operating income - 15,606.60 0.00 0.00
264 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidary Any other transaction Other operating income - 14,111.50 0.00 0.00
265 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidary Sale of fixed assets - 5.50 0.00 0.00
266 Glenmark Pharmaceuticals Limited GLENMARK GENERICS S.A. Wholly Owned Subsidary Purchase of goods or services - 106.50 0.00 0.00
267 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc Wholly Owned Subsidary Purchase of goods or services - 2,353.60 0.00 0.00
268 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidary Purchase of goods or services - 1,563.10 0.00 0.00
269 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C Wholly Owned Subsidary Purchase of goods or services - 8,509.40 0.00 0.00
270 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidary Purchase of goods or services - 0.20 0.00 0.00
271 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc. Wholly Owned Subsidary Purchase of goods or services - 128.80 0.00 0.00
272 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidary Purchase of goods or services - 2,622.50 0.00 0.00
273 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Limited Wholly Owned Subsidary Purchase of goods or services - 16.90 0.00 0.00
274 Glenmark Pharmaceuticals Limited Glenmark Singapore Pte Ltd Wholly Owned Subsidary Purchase of goods or services - 548.10 0.00 0.00
275 Glenmark Pharmaceuticals Limited GLENMARK ARZNEIMITTEL GmBH - GERMANY Wholly Owned Subsidary Purchase of goods or services - 169.90 0.00 0.00
276 Glenmark Pharmaceuticals Limited Glenmark Ukraine LLC Wholly Owned Subsidary Purchase of goods or services - 131.80 0.00 0.00
277 Glenmark Pharmaceuticals Limited IGI Therapeutics SA Wholly Owned Subsidary Purchase of goods or services - (59.00) 0.00 0.00
278 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidary Purchase of goods or services - 68.10 0.00 0.00
279 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly Owned Subsidary Any other transaction Purchase of Tangibles/Capex - 2,563.50 0.00 0.00
280 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidary Any other transaction Loan Given - 318.30 0.00 0.00 Loan 8.74 5 years Unsecured Working Capital
281 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E. Wholly Owned Subsidary Any other transaction Loan given to WOS converted into Investment - 2,125.40 0.00 0.00
282 Glenmark Pharmaceuticals Limited Glenmark Holding S.A Wholly Owned Subsidary Any other transaction Loan repaid by - 57,956.40 0.00 0.00
283 Glenmark Pharmaceuticals Limited Glenmark Holding S.A Wholly Owned Subsidary Interest received - 8,654.60 0.00 0.00
284 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd, Kenya Wholly Owned Subsidary Interest received - 78.30 0.00 0.00
285 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co Ltd Wholly Owned Subsidary Interest received - 3.70 0.00 0.00
286 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E., Egypt Wholly Owned Subsidary Interest received - 56.30 0.00 0.00
287 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidary Interest received - 124.70 0.00 0.00
288 Glenmark Pharmaceuticals Limited Glenmark Holding S.A., Switzerland Wholly Owned Subsidary Any other transaction Other Income - 132.70 0.00 0.00
289 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidary Any other transaction Other Income - 7.20 0.00 0.00
290 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly Owned Subsidary Any other transaction Other Income - 138.20 0.00 0.00
291 Glenmark Pharmaceuticals Limited Glenmark Foundation Other related party Any other transaction CSR Contribution - 366.90 0.00 0.00
292 Glenmark Pharmaceuticals Limited Glenmark Aquatic Foundation Other related party Any other transaction CSR Contribution - 346.00 0.00 0.00
293 Glenmark Pharmaceuticals Limited Mr. Glenn Saldanha Chairman & Managing Director (Promoter) Remuneration - 606.80 0.00 0.00
294 Glenmark Pharmaceuticals Limited Mrs. Cherylann Pinto Executive Director (Promoter) Remuneration - 106.90 0.00 0.00
295 Glenmark Pharmaceuticals Limited Mrs. Blanche Saldanha Non Executive Director (Promoter) Any other transaction Sitting Fees - 4.00 0.00 0.00
296 Glenmark Pharmaceuticals Limited Glenmark Arzneimittel GmbH Wholly Owned Subsidary Any other transaction Payable - 0.00 2,003.90 2,431.90
297 Glenmark Pharmaceuticals Limited Glenmark Farmaceutica Ltda., Brazil Wholly Owned Subsidary Any other transaction Receivable - 0.00 14,954.60 7,401.40
298 Glenmark Pharmaceuticals Limited Glenmark Philippines Inc., Philippines Wholly Owned Subsidary Any other transaction Receivable - 0.00 5,974.10 5,041.40
299 Glenmark Pharmaceuticals Limited Glenmark Therapeutics Inc., USA Wholly Owned Subsidary Any other transaction Receivable - 0.00 584.60 1,535.10
300 Glenmark Pharmaceuticals Limited IGI Therapeutics SA Wholly Owned Subsidary Any other transaction Receivable - 0.00 855.70 16,614.40
301 Glenmark Pharmaceuticals Limited Glenmark Holding S.A., Switzerland Wholly Owned Subsidary Any other transaction Loan Given - 0.00 5,67,479.10 5,27,632.00
302 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Nigeria) Ltd Wholly Owned Subsidary Any other transaction Receivable - 0.00 3,314.10 3,314.10
303 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Nigeria) Ltd Wholly Owned Subsidary Any other transaction Loan Given - 0.00 1,152.60 1,152.60
304 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C., Russia Wholly Owned Subsidary Any other transaction Receivable - 0.00 16,311.10 16,413.50
305 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly Owned Subsidary Any other transaction Receivable - 0.00 6,298.70 7,490.90
306 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE. Wholly Owned Subsidary Any other transaction Payable - 0.00 7,016.70 3,414.20
307 Glenmark Pharmaceuticals Limited Glenmark Generics SA., Argentina Wholly Owned Subsidary Any other transaction Receivable - 0.00 264.80 407.00
308 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Venezuela., C.A Wholly Owned Subsidary Any other transaction Receivable - 0.00 15,582.00 15,582.00
309 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn.Bhd. Wholly Owned Subsidary Any other transaction Receivable - 0.00 4,413.50 3,660.00
310 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC. Wholly Owned Subsidary Any other transaction Receivable - 0.00 115.90 213.90
311 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidary Any other transaction Receivable - 0.00 3,827.50 824.80
312 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly Owned Subsidary Any other transaction Payable - 0.00 35,373.00 84,211.30
313 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidary Any other transaction Receivable - 0.00 16,101.10 17,341.30
314 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals SK, s.r.o., Slovak Republic Wholly Owned Subsidary Any other transaction Payable - 0.00 0.10 0.10
315 Glenmark Pharmaceuticals Limited Glenmark Distributors Sp. Z.O.O Wholly Owned Subsidary Any other transaction Payable - 0.00 1.60 1.60
316 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd Wholly Owned Subsidary Any other transaction Receivable - 0.00 593.60 697.60
317 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd Wholly Owned Subsidary Any other transaction Loan Given - 0.00 171.60 182.10
318 Glenmark Pharmaceuticals Limited Glenmark Uruguay S.A. Wholly Owned Subsidary Any other transaction Payable - 0.00 8,493.70 8,826.70
319 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia Ltda. Wholly Owned Subsidary Any other transaction Receivable - 0.00 2,037.80 996.20
320 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd. Wholly Owned Subsidary Any other transaction Receivable - 0.00 19,249.80 17,137.20
321 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd. Wholly Owned Subsidary Any other transaction Loan Given - 0.00 1,709.00 1,810.20
322 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 7,164.70 8,304.20
323 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E. Wholly Owned Subsidary Any other transaction Loan Given - 0.00 3,163.20 1,080.30
324 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc. Wholly Owned Subsidary Any other transaction Receivable - 0.00 6,575.10 4,153.70
325 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 62,534.50 20,171.70
326 Glenmark Pharmaceuticals Limited Glenmark Ukraine LLC Wholly Owned Subsidary Any other transaction Receivable - 0.00 5,402.90 4,207.50
327 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ecuador S.A. Wholly Owned Subsidary Any other transaction Receivable - 0.00 2,525.30 600.30
328 Glenmark Pharmaceuticals Limited GLENMARK PHARMACEUTICALS SINGAPORE Wholly Owned Subsidary Any other transaction Payable - 0.00 449.60 555.80
329 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Australia Wholly Owned Subsidary Any other transaction Receivable - 0.00 454.70 859.50
330 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidary Any other transaction Receivable - 0.00 2,916.30 3,349.00
331 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico S.A. DE C.V. Mexico Wholly Owned Subsidary Any other transaction Receivable - 0.00 917.10 917.10
332 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC., Peru Wholly Owned Subsidary Any other transaction Receivable - 0.00 0.10 0.10
333 Glenmark Specialty S.A. IGI Therapeutics SA Wholly Owned Subsidary Any other transaction Expense - 4.80 0.00 0.00
Total value of transaction during the reporting period 14,47,474.80



Text Block

Textual Information(1) Loan Given
Textual Information(2) Loan Given